Reference:
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Dasatinib and nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: A systematic review and economic evaluation. Health Technology Assessment 2012;16(22): 1-410.